Jim Cramer Says He “Should Have Been Recommending Regeneron”

REGN +0.73% AMGN -0.96%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer answered questions about. Answering a caller’s query about the stock, Cramer stated:

“I should have been recommending Regeneron. That Len Schleifer pulled the rabbit out of a hat. It’s coming right back right now. By the way, I’ll give you a twofer, so is Amgen.”

Stock market data showing an upward trajectory. Photo by Burak The Weekender on Pexels

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. During the last week of April, Cramer mentioned the stock while discussing the best-performing stocks of the last 2 decades. He remarked:

“Rearrange Repligen’s ticker just a bit and you’ll get the ninth best stock of the Mad Money era, Regeneron Pharma, that’s up more than 9,400%. Now this one’s special to me because Regeneron’s co-founder and CEO, Dr. Len Schleifer, he was one of the first guests who ever came on the show back in April 12th, 2005. The stock was trading at less than five bucks a share. Now it’s at $568, and that’s after 6.87% beating today.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.